5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Infusion O
Reactions O
: O
Immediately O
stop O
and O
permanently O
discontinue O
Erbitux O
for O
serious O
infusion O
reactions O
. O

Monitor O
patients O
following O
infusion O
. O

( O
5.1 O
) O
* O
Cardiopulmonary O
Arrest O
: O
Closely O
monitor O
serum O
electrolytes O
during O
and O
after O
Erbitux O
. O

( O
5.2 O
, O
5.6 O
) O
* O
Pulmonary O
Toxicity O
: O
Interrupt O
therapy O
for O
acute O
onset O
or O
worsening O
of O
pulmonary O
symptoms O
. O

( O
5.3 O
) O
* O
Dermatologic O
Toxicity O
: O
Mucocutaneous O
adverse O
reactions O
. O

Limit O
sun O
exposure O
. O

Monitor O
for O
inflammatory O
or O
infectious O
sequelae O
. O

( O
2.4 O
, O
5.4 O
) O
* O
Hypomagnesemia O
: O
Periodically O
monitor O
during O
and O
for O
at O
least O
8 O
weeks O
following O
the O
completion O
of O
Erbitux O
. O

Replete O
electrolytes O
as O
necessary O
. O

( O
5.6 O
) O
* O
Increased O
tumor O
progression O
, O
increased O
mortality O
, O
or O
lack O
of O
benefit O
in O
patients O
with O
Ras O
-mutant O
mCRC O
. O

( O
5.7 O
) O
5.1 O
Infusion O
Reactions O
Serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
requiring O
medical O
intervention O
and O
immediate O
, O
permanent O
discontinuation O
of O
Erbitux O
included O
rapid O
onset O
of O
airway B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
( O
bronchospasm B-OSE_Labeled_AE
, O
stridor B-OSE_Labeled_AE
, O
hoarseness B-OSE_Labeled_AE
) O
, O
hypotension B-OSE_Labeled_AE
, O
shock B-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
and/or O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
. O

Severe O
( O
NCI O
CTC O
Grades O
3 O
and O
4 O
) O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
in O
2-5 O
% O
of O
1373 O
patients O
in O
Studies O
1 O
, O
3 O
, O
5 O
, O
and O
6 O
receiving O
Erbitux O
, O
with O
fatal B-NonOSE_AE
outcome O
in O
1 O
patient O
. O

[ O
See O
Clinical O
Studies O
( O
14.1 O
, O
14.2 O
) O
. O
] O

Approximately O
90 O
% O
of O
severe O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
with O
the O
first O
infusion O
despite O
premedication O
with O
antihistamines O
. O

Monitor O
patients O
for O
1 O
hour O
following O
Erbitux O
infusions O
in O
a O
setting O
with O
resuscitation O
equipment O
and O
other O
agents O
necessary O
to O
treat O
anaphylaxis B-NonOSE_AE
( O
eg O
, O
epinephrine O
, O
corticosteroids O
, O
intravenous O
antihistamines O
, O
bronchodilators O
, O
and O
oxygen O
) O
. O

Monitor O
longer O
to O
confirm O
resolution O
of O
the O
event O
in O
patients O
requiring O
treatment O
for O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

Immediately O
and O
permanently O
discontinue O
Erbitux O
in O
patients O
with O
serious O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

[ O
See O
Boxed O
Warning O
, O
Dosage O
and O
Administration O
( O
2.4 O
) O
. O
] O

5.2 O
Cardiopulmonary O
Arrest O
Cardiopulmonary B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
and/or O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
occurred O
in O
4 O
( O
2 O
% O
) O
of O
208 O
patients O
treated O
with O
radiation O
therapy O
and O
Erbitux O
as O
compared O
to O
none O
of O
212 O
patients O
treated O
with O
radiation O
therapy O
alone O
in O
Study O
1 O
. O

Three O
patients O
with O
prior O
history O
of O
coronary B-Not_AE_Candidate
artery I-Not_AE_Candidate
disease I-Not_AE_Candidate
died B-NonOSE_AE
at O
home O
, O
with O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
as O
the O
presumed O
cause O
of O
death B-NonOSE_AE
. O

One O
of O
these O
patients O
had O
arrhythmia B-Not_AE_Candidate
and O
one O
had O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
. O

Death B-NonOSE_AE
occurred O
27 O
, O
32 O
, O
and O
43 O
days O
after O
the O
last O
dose O
of O
Erbitux O
. O

One O
patient O
with O
no O
prior O
history O
of O
coronary B-NonOSE_AE
artery I-NonOSE_AE
disease I-NonOSE_AE
died B-NonOSE_AE
one O
day O
after O
the O
last O
dose O
of O
Erbitux O
. O

In O
Study O
2 O
, O
fatal B-NonOSE_AE
cardiac B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
and/or O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
occurred O
in O
7 O
( O
3 O
% O
) O
of O
219 O
patients O
treated O
with O
EU-approved O
cetuximab O
and O
platinum-based O
therapy O
with O
5-FU O
as O
compared O
to O
4 O
( O
2 O
% O
) O
of O
215 O
patients O
treated O
with O
chemotherapy O
alone O
. O

Five O
of O
these O
7 O
patients O
in O
the O
chemotherapy O
plus O
cetuximab O
arm O
received O
concomitant O
cisplatin O
and O
2 O
patients O
received O
concomitant O
carboplatin O
. O

All O
4 O
patients O
in O
the O
chemotherapy-alone O
arm O
received O
cisplatin O
. O

Carefully O
consider O
use O
of O
Erbitux O
in O
combination O
with O
radiation O
therapy O
or O
platinum-based O
therapy O
with O
5-FU O
in O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
with O
a O
history O
of O
coronary B-Not_AE_Candidate
artery I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
arrhythmias B-Not_AE_Candidate
in O
light O
of O
these O
risks O
. O

Closely O
monitor O
serum O
electrolytes O
, O
including O
serum O
magnesium O
, O
potassium O
, O
and O
calcium O
, O
during O
and O
after O
Erbitux O
. O

[ O
See O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.6 O
) O
. O
] O

5.3 O
Pulmonary B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ILD I-OSE_Labeled_AE
) O
, O
including O
1 O
fatality B-NonOSE_AE
, O
occurred O
in O
4 O
of O
1570 O
( O
< O
0.5 O
% O
) O
patients O
receiving O
Erbitux O
in O
Studies O
1 O
, O
3 O
, O
and O
6 O
, O
as O
well O
as O
other O
studies O
, O
in O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
and O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

Interrupt O
Erbitux O
for O
acute O
onset O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
pulmonary I-NonOSE_AE
symptoms I-NonOSE_AE
. O

Permanently O
discontinue O
Erbitux O
for O
confirmed O
ILD B-NonOSE_AE
. O

5.4 O
Dermatologic O
Toxicity O
Dermatologic B-OSE_Labeled_AE
toxicities I-OSE_Labeled_AE
, O
including O
acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
drying I-OSE_Labeled_AE
and O
fissuring O
, O
paronychial B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
, O
infectious B-OSE_Labeled_AE
sequelae I-OSE_Labeled_AE
( O
for O
example O
, O
S B-OSE_Labeled_AE
. I-OSE_Labeled_AE
aureus I-OSE_Labeled_AE
sepsis I-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
formation I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
blepharitis B-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
, O
keratitis B-OSE_Labeled_AE
/ O
ulcerative B-OSE_Labeled_AE
keratitis I-OSE_Labeled_AE
with O
decreased B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
acuity I-OSE_Labeled_AE
, O
cheilitis B-OSE_Labeled_AE
) O
, O
and O
hypertrichosis B-OSE_Labeled_AE
occurred O
in O
patients O
receiving O
Erbitux O
therapy O
. O

Acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
occurred O
in O
76-88 O
% O
of O
1373 O
patients O
receiving O
Erbitux O
in O
Studies O
1 O
, O
3 O
, O
5 O
, O
and O
6 O
. O

Severe O
acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
occurred O
in O
1-17 O
% O
of O
patients O
. O

Acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
usually O
developed O
within O
the O
first O
two O
weeks O
of O
therapy O
and O
resolved O
in O
a O
majority O
of O
the O
patients O
after O
cessation O
of O
treatment O
, O
although O
in O
nearly O
half O
, O
the O
event O
continued O
beyond O
28 O
days O
. O

Life-threatening O
and O
fatal B-NonOSE_AE
bullous B-OSE_Labeled_AE
mucocutaneous I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
with O
blisters O
, O
erosions O
, O
and O
skin O
sloughing O
has O
also O
been O
observed O
in O
patients O
treated O
with O
Erbitux O
. O

It O
could O
not O
be O
determined O
whether O
these O
mucocutaneous B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
were O
directly O
related O
to O
EGFR B-NonOSE_AE
inhibition I-NonOSE_AE
or O
to O
idiosyncratic O
immune B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
effects I-NonOSE_AE
( O
eg O
, O
Stevens B-NonOSE_AE
- I-NonOSE_AE
Johnson I-NonOSE_AE
syndrome I-NonOSE_AE
or O
toxic B-NonOSE_AE
epidermal I-NonOSE_AE
necrolysis I-NonOSE_AE
) O
. O

Monitor O
patients O
receiving O
Erbitux O
for O
dermatologic B-NonOSE_AE
toxicities I-NonOSE_AE
and O
infectious B-NonOSE_AE
sequelae I-NonOSE_AE
. O

Instruct O
patients O
to O
limit O
sun O
exposure O
during O
Erbitux O
therapy O
. O

[ O
See O
Dosage O
and O
Administration O
( O
2.4 O
) O
. O
] O

5.5 O
Use O
of O
Erbitux O
in O
Combination O
With O
Radiation O
and O
Cisplatin O
In O
a O
controlled O
study O
, O
940 O
patients O
with O
locally O
advanced O
SCCHN B-Not_AE_Candidate
were O
randomized O
1:1 O
to O
receive O
either O
Erbitux O
in O
combination O
with O
radiation O
therapy O
and O
cisplatin O
or O
radiation O
therapy O
and O
cisplatin O
alone O
. O

The O
addition O
of O
Erbitux O
resulted O
in O
an O
increase O
in O
the O
incidence O
of O
Grade O
3-4 O
mucositis B-OSE_Labeled_AE
, O
radiation B-OSE_Labeled_AE
recall I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
and O
electrolyte B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
compared O
to O
radiation O
and O
cisplatin O
alone O
. O

Adverse O
reactions O
with O
fatal B-NonOSE_AE
outcome O
were O
reported O
in O
20 O
patients O
( O
4.4 O
% O
) O
in O
the O
Erbitux O
combination O
arm O
and O
14 O
patients O
( O
3.0 O
% O
) O
in O
the O
control O
arm O
. O

Nine O
patients O
in O
the O
Erbitux O
arm O
( O
2.0 O
% O
) O
experienced O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
compared O
to O
4 O
patients O
( O
0.9 O
% O
) O
in O
the O
control O
arm O
. O

The O
main O
efficacy O
outcome O
of O
the O
study O
was O
progression-free O
survival O
( O
PFS O
) O
. O

The O
addition O
of O
Erbitux O
to O
radiation O
and O
cisplatin O
did O
not O
improve O
PFS O
. O

5.6 O
Hypomagnesemia O
and O
Electrolyte O
Abnormalities O
In O
patients O
evaluated O
during O
clinical O
trials O
, O
hypomagnesemia B-OSE_Labeled_AE
occurred O
in O
55 O
% O
of O
365 O
patients O
receiving O
Erbitux O
in O
Study O
5 O
and O
two O
other O
clinical O
trials O
in O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
and O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
respectively O
, O
and O
was O
severe O
( O
NCI O
CTC O
Grades O
3 O
and O
4 O
) O
in O
6-17 O
% O
. O

In O
Study O
2 O
, O
where O
EU-approved O
cetuximab O
was O
administered O
in O
combination O
with O
platinum-based O
therapy O
, O
the O
addition O
of O
cetuximab O
to O
cisplatin O
and O
5-FU O
resulted O
in O
an O
increased O
incidence O
of O
hypomagnesemia B-OSE_Labeled_AE
( O
14 O
% O
vs O
. O
6 O
% O
) O
and O
of O
Grade O
3-4 O
hypomagnesemia B-OSE_Labeled_AE
( O
7 O
% O
vs O
. O
2 O
% O
) O
compared O
to O
cisplatin O
and O
5-FU O
alone O
. O

In O
contrast O
, O
the O
incidences O
of O
hypomagnesemia B-NonOSE_AE
were O
similar O
for O
those O
who O
received O
cetuximab O
, O
carboplatin O
, O
and O
5-FU O
compared O
to O
carboplatin O
and O
5-FU O
( O
4 O
% O
vs O
. O
4 O
% O
) O
. O

No O
patient O
experienced O
Grade O
3-4 O
hypomagnesemia B-NonOSE_AE
in O
either O
arm O
in O
the O
carboplatin O
subgroup O
. O

The O
onset O
of O
hypomagnesemia B-OSE_Labeled_AE
and O
accompanying O
electrolyte B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
occurred O
days O
to O
months O
after O
initiation O
of O
Erbitux O
. O

Periodically O
monitor O
patients O
for O
hypomagnesemia B-NonOSE_AE
, O
hypocalcemia B-NonOSE_AE
, O
and O
hypokalemia B-NonOSE_AE
, O
during O
and O
for O
at O
least O
8 O
weeks O
following O
the O
completion O
of O
Erbitux O
. O

Replete O
electrolytes O
as O
necessary O
. O

5.7 O
Increased O
Tumor O
Progression O
, O
Increased O
Mortality O
, O
or O
Lack O
of O
Benefit O
in O
Patients O
with O
Ras O
-Mutant O
mCRC O
Erbitux O
is O
not O
indicated O
for O
the O
treatment O
of O
patients O
with O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
that O
harbor O
somatic O
mutations O
in O
exon O
2 O
( O
codons O
12 O
and O
13 O
) O
, O
exon O
3 O
( O
codons O
59 O
and O
61 O
) O
, O
and O
exon O
4 O
( O
codons O
117 O
and O
146 O
) O
of O
either O
K-Ras O
or O
N-Ras O
and O
hereafter O
is O
referred O
to O
as O
`` O
Ras O
. O
'' O

Retrospective O
subset O
analyses O
of O
Ras O
-mutant O
and O
wild-type O
populations O
across O
several O
randomized O
clinical O
trials O
including O
Study O
4 O
were O
conducted O
to O
investigate O
the O
role O
of O
Ras O
mutations O
on O
the O
clinical O
effects O
of O
anti-EGFR-directed O
monoclonal O
antibodies O
. O

Use O
of O
cetuximab O
in O
patients O
with O
Ras O
mutations O
resulted O
in O
no O
clinical O
benefit O
with O
treatment O
related O
toxicity O
. O

[ O
See O
Indications O
and O
Usage O
( O
1.2 O
) O
, O
Clinical O
Pharmacology O
( O
12.1 O
) O
, O
Clinical O
Studies O
( O
14.2 O
) O
. O
] O

5.8 O
Epidermal O
Growth O
Factor O
Receptor O
( O
EGFR O
) O
Expression O
and O
Response O
Because O
expression O
of O
EGFR O
has O
been O
detected O
in O
nearly O
all O
SCCHN B-NonOSE_AE
tumor I-NonOSE_AE
specimens O
, O
patients O
enrolled O
in O
the O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
clinical O
studies O
were O
not O
required O
to O
have O
immunohistochemical O
evidence O
of O
EGFR B-NonOSE_AE
tumor I-NonOSE_AE
expression I-NonOSE_AE
prior O
to O
study O
entry O
. O

Patients O
enrolled O
in O
the O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
clinical O
studies O
were O
required O
to O
have O
immunohistochemical O
evidence O
of O
EGFR B-NonOSE_AE
tumor I-NonOSE_AE
expression I-NonOSE_AE
. O

Primary B-NonOSE_AE
tumor I-NonOSE_AE
or O
tumor B-NonOSE_AE
from I-NonOSE_AE
a I-NonOSE_AE
metastatic I-NonOSE_AE
site I-NonOSE_AE
was O
tested O
with O
the O
DakoCytomation O
EGFR O
pharmDxTM O
test O
kit O
. O

Specimens O
were O
scored O
based O
on O
the O
percentage O
of O
cells O
expressing O
EGFR O
and O
intensity O
( O
barely/faint O
, O
weak-to-moderate O
, O
and O
strong O
) O
. O

Response O
rate O
did O
not O
correlate O
with O
either O
the O
percentage O
of O
positive O
cells O
or O
the O
intensity O
of O
EGFR O
expression O
. O

